GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Shiller PE Ratio

AEterna Zentaris (TSX:AEZS) Shiller PE Ratio : (As of May. 11, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Shiller PE Ratio Historical Data

The historical data trend for AEterna Zentaris's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Shiller PE Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Shiller PE Ratio

For the Biotechnology subindustry, AEterna Zentaris's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Shiller PE Ratio falls into.



AEterna Zentaris Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AEterna Zentaris's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-6.225/125.4675*125.4675
=-6.225

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -888.560 98.604 -1,130.635
201406 -974.700 99.473 -1,229.407
201409 -2,202.200 99.394 -2,779.883
201412 915.641 98.367 1,167.903
201503 -1,714.786 99.789 -2,156.042
201506 -1,687.822 100.500 -2,107.124
201509 -883.516 100.421 -1,103.874
201512 -138.364 99.947 -173.693
201603 -48.936 101.054 -60.759
201606 -91.547 102.002 -112.608
201609 -79.959 101.765 -98.583
201612 -97.375 101.449 -120.430
201703 -41.500 102.634 -50.733
201706 -23.931 103.029 -29.143
201709 -74.902 103.345 -90.936
201712 1.277 103.345 1.550
201803 112.517 105.004 134.445
201806 -21.000 105.557 -24.961
201809 -19.551 105.636 -23.221
201812 -42.995 105.399 -51.181
201903 -40.113 106.979 -47.045
201906 1.329 107.690 1.548
201909 -2.648 107.611 -3.087
201912 -5.268 107.769 -6.133
202003 5.584 107.927 6.492
202006 -20.328 108.401 -23.528
202009 -2.646 108.164 -3.069
202012 -2.679 108.559 -3.096
202103 -2.514 110.298 -2.860
202106 -2.102 111.720 -2.361
202109 -2.027 112.905 -2.253
202112 -3.226 113.774 -3.558
202203 -2.735 117.646 -2.917
202206 -4.456 120.806 -4.628
202209 -3.735 120.648 -3.884
202212 -13.911 120.964 -14.429
202303 -4.816 122.702 -4.925
202306 -2.763 124.203 -2.791
202309 -4.601 125.230 -4.610
202312 -6.225 125.468 -6.225

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (TSX:AEZS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AEterna Zentaris Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (TSX:AEZS) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.